Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 16, 2022; 10(32): 11690-11701
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11690
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11690
USPs | Expression | Potential role in breast cancer | Signal pathway |
USP1 | Upregulated | Tumor promoter | KPNA2, ERα signaling, Hippo signaling pathway, TGF-β signaling[20-23] |
USP4 | Upregulated | Tumor suppressor | PDCD4, circBMPR2, PAK5-DNPEP pathway, Relaxin/TGF-β1/Smad2/MMP-9 signaling, TGF-β signaling[24-28] |
USP7 | Upregulated | Tumor promoter | PHF8,DNA repair, Aurora-A kinase, ECT2[29-34] |
USP9X | Upregulated | Tumor promoter, Tumor suppressor | CEP131, Hippo Pathway, Notch signaling, Cyclin D1,Wnt signaling, TRAIL, YAP1[35,37,38,40,41,45,46] |
USP11 | Upregulated | Tumor promoter | TGFβ signaling, DNA damage, XIAP[47-49] |
USP14 | Upregulated | Tumor promoter | CyclinB1, Wnt/β-catenin and PI3K/AKT pathways, cell cycle[53,54] |
USP15 | Upregulated | Tumor promoter | DNA repair, ERα signaling[65,66] |
USP18 | Upregulated | Tumor promoter | AKT/Skp2 pathway[68] |
USP20 | Upregulated | Tumor promoter | SNAI2[69] |
USP22 | Upregulated | Tumor promoter | c-Myc, Hh pathway[57,58] |
USP28 | Upregulated | Tumor suppressor | HIF-independent pathway, LSD1[71,72] |
USP32 | Upregulated | Tumor promoter | Unknown[73] |
USP33 | Upregulated | Tumor suppressor | Slit-Robo signaling[74] |
USP37 | Upregulated | Tumor promoter | Stemness, epithelial-mesenchymal transition[60] |
USP39 | Upregulated | Tumor promoter | G0/G1-phase arrest, CHEK2[62,63] |
- Citation: Huang ML, Shen GT, Li NL. Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment. World J Clin Cases 2022; 10(32): 11690-11701
- URL: https://www.wjgnet.com/2307-8960/full/v10/i32/11690.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i32.11690